A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)

Recruiting

Phase 1

LetermovirA Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)

Sponsor:

Merck Sharp & Dohme LLC

Code:

NCT07199465

Conditions

Cytomegalovirus Prophylaxis

Eligibility Criteria

Sex: All

Age: 0 - 17

Healthy Volunteers: Not accepted

Interventions

Letermovir

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-09. This information was provided to ClinicalTrials.gov by Merck Sharp & Dohme LLC on 2025-10-30.